Bayer’s Rally Rests on a Legal Victory and a Fresh Trade Battle – But the Charts Flash Overbought
Published on 07/04/2026 at 17:07 | Redaktion boerse-global.de
Bayer’s stock capped the week at €53.04, just a whisker shy of its new 52-week high, after a landmark US Supreme Court ruling handed the company a critical win in the glyphosate saga. Yet for all the euphoria, two looming dates and a freshly ignited trade dispute threaten to turn the mood sour. The rally that has nearly doubled the share price over the past twelve months is starting to look extended, and a growing number of analysts are warning that the odds of a pullback are rising.
The Supreme Court’s 7-2 decision in Monsanto v. Durnell effectively shut down thousands of failure-to-warn claims by ruling that federal law pre-empts state-level lawsuits over cancer warnings on herbicide labels. Bayer moved quickly to capitalise on the legal clarity by bundling its US glyphosate business into a new subsidiary, Ruveon LLC. Deutsche Bank promptly upgraded the stock to “Buy” with a €60 price target, arguing that a break-up of Bayer’s portfolio is now a matter of “when and how, not if.” The shares have gained roughly 103% over the past year and almost 40% since January alone.
But the path to a clean slate is far from straight. The anti-dumping petition that Bayer and Ruveon filed against Chinese glyphosate imports has drawn sharp opposition from US farming groups – the same organisations that backed the company during the Supreme Court fight. The outcome of that trade complaint is highly uncertain and adds a geopolitical layer to what was already a complex legal picture.
Should investors sell immediately? Or is it worth buying Bayer?
More immediately, the next major checkpoint is 19 August 2026, when a Missouri court is scheduled to rule on final approval of the multi-billion-dollar class-action settlement. Bayer welcomed the court’s decision to postpone the hearing to that date, but even a green light would not end the litigation: plaintiffs can appeal, and the settlement would only become final once all appeal proceedings are exhausted – a process that could take years.
Technically, the warning signals are hard to ignore. The relative strength index stands at 85, deep in overbought territory, and the share price has detached more than 36% from its 50-day moving average. A correction from these levels would come as no surprise, with the first line of support at €38.86 (the 50-day average) and a second floor at €37.11 (the 200-day average). The high volatility of recent weeks underscores the nervousness lurking behind the rally.
Before the August hearing, Bayer will release second-quarter figures on 4 August. Those numbers will offer investors a first look at how the Ruveon restructuring is affecting the balance sheet and whether the legal costs continue to weigh on operating performance. Until then, the stock remains caught between a powerful legal tailwind and the growing list of risks that could puncture the momentum.
Ad
Bayer Stock: New Analysis - 4 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
